Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
06 2019
Historique:
received: 31 10 2018
accepted: 06 02 2019
pubmed: 2 3 2019
medline: 6 8 2020
entrez: 2 3 2019
Statut: ppublish

Résumé

Metformin is an important antidiabetic drug and often used as a probe for drug-drug interactions (DDIs) mediated by renal transporters. Despite evidence supporting the inhibition of multidrug and toxin extrusion proteins as the likely DDI mechanism, the previously reported physiologically-based pharmacokinetic (PBPK) model required the substantial lowering of the inhibition constant values of cimetidine for multidrug and toxin extrusion proteins from those obtained in vitro to capture the clinical DDI data between metformin and cimetidine.

Identifiants

pubmed: 30821133
doi: 10.1002/psp4.12398
pmc: PMC6617824
doi:

Substances chimiques

Cimetidine 80061L1WGD
Metformin 9100L32L2N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-406

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

J Pharm Sci. 2005 Jun;94(6):1259-76
pubmed: 15858854
Drug Metab Dispos. 2018 May;46(5):749-757
pubmed: 29440178
Clin Pharmacol Ther. 2016 Nov;100(5):513-523
pubmed: 27170342
Diabetologia. 2013 Sep;56(9):1898-906
pubmed: 23835523
Pharmacogenet Genomics. 2008 Jul;18(7):637-45
pubmed: 18551044
J Pharmacol Exp Ther. 2012 Feb;340(2):393-403
pubmed: 22072731
Clin Pharmacokinet. 2014 Sep;53(9):837-47
pubmed: 25117183
Br J Clin Pharmacol. 2013 Nov;76(5):787-96
pubmed: 23305245
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400-7
pubmed: 26974526
Eur J Clin Pharmacol. 1979 Sep;16(3):195-202
pubmed: 499320
Clin Pharmacokinet. 2015 Aug;54(8):811-24
pubmed: 25943187
Br J Clin Pharmacol. 1981 Aug;12(2):235-46
pubmed: 7306436
Pharmacol Res Perspect. 2017 Oct;5(5):
pubmed: 28971610
Pharmacogenet Genomics. 2011 Dec;21(12):837-50
pubmed: 21989078
Clin Pharmacokinet. 2011 Feb;50(2):81-98
pubmed: 21241070
Biochem Pharmacol. 2007 Jul 15;74(2):359-71
pubmed: 17509534
Clin Pharmacol Ther. 2013 Feb;93(2):186-94
pubmed: 23267855
J Pharmacol Exp Ther. 2016 Dec;359(3):401-410
pubmed: 27758931
Br J Clin Pharmacol. 1989 Mar;27(3):381-6
pubmed: 2785812
Diabetes Care. 1994 Oct;17(10):1100-9
pubmed: 7821128
Xenobiotica. 2007 Aug;37(8):818-31
pubmed: 17701831
Eur J Clin Nutr. 2004 Feb;58(2):270-6
pubmed: 14749747
Pharm Res. 2017 Aug;34(8):1584-1600
pubmed: 28397089
Drug Metab Dispos. 2016 Mar;44(3):356-64
pubmed: 26700958
J Pharmacokinet Biopharm. 1998 Oct;26(5):495-519
pubmed: 10205768
Annu Rev Pharmacol Toxicol. 2013;53:581-612
pubmed: 23140240
Br J Clin Pharmacol. 1987 May;23(5):545-51
pubmed: 3593625
Clin Pharmacokinet. 1996 May;30(5):359-71
pubmed: 8743335
Pharmacogenet Genomics. 2013 Oct;23(10):526-34
pubmed: 23873119
Diabetes Obes Metab. 2016 Jan;18(1):104-8
pubmed: 26381793
Eur J Clin Pharmacol. 1981;19(5):343-7
pubmed: 7238562
J Pharmacol Exp Ther. 2009 Feb;328(2):652-62
pubmed: 19001154
Biopharm Drug Dispos. 2014 Jan;35(1):15-32
pubmed: 24218242
Pharm Res. 2005 Feb;22(2):255-9
pubmed: 15783073
J Hum Genet. 2007;52(2):117-122
pubmed: 17111267
Clin Pharmacol Ther. 2011 Jun;89(6):837-44
pubmed: 21544077
J Pharmacol Exp Ther. 2015 Aug;354(2):225-9
pubmed: 26062557
J Physiol. 1949 Mar 1;108(1):37-77
pubmed: 18128147
Eur J Pharm Sci. 2016 Jun 10;88:70-82
pubmed: 27019345
Mol Pharmacol. 2009 Jun;75(6):1280-6
pubmed: 19332510
Eur J Clin Pharmacol. 1979 Nov;16(5):335-40
pubmed: 520401
Drug Saf. 1999 Apr;20(4):377-84
pubmed: 10230584
Clin Pharmacol Ther. 2013 Jul;94(1):126-41
pubmed: 23588320
J Am Soc Nephrol. 2006 Aug;17(8):2127-35
pubmed: 16807400
Drug Metab Dispos. 2017 Jul;45(7):779-789
pubmed: 28468836
Drug Metab Dispos. 2015 Jul;43(7):984-93
pubmed: 25904762
Eur J Clin Pharmacol. 2015 Jan;71(1):85-94
pubmed: 25552403

Auteurs

Kotaro Nishiyama (K)

Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Hyogo, Japan.

Kota Toshimoto (K)

Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, Yokohama, Kanagawa, Japan.

Wooin Lee (W)

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.

Naoki Ishiguro (N)

Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Hyogo, Japan.

Bojan Bister (B)

Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Hyogo, Japan.

Yuichi Sugiyama (Y)

Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, Yokohama, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH